人sCD40L转基因小鼠模型的构建

目的研究阻断CD40-CD40L共刺激信号通路对移植皮肤免疫排斥反应的影响。方法通过RT-PCR技术克隆了呈可溶性表达的CD40L分子胞外区(sCD40L),利用K14启动子构建了sCD40L皮肤特异性表达载体,并利用该载体制备了转基因小鼠。结果所克隆的CD40L胞外区片段其大小及序列符合预期;以哺乳动物表达载体PCI为骨架,通过DNA重组,获得了含K14启动子和sCD40L编码区的皮肤特异性表达载体K14-sCD40L;通过显微注射和胚胎移植,PCR筛选检测:49只G0代小鼠有1只小鼠扩增出特异性条带,阴性对照无条带。结论成功建立sCD40L转基因阳性小鼠。     

通过双原核显微注射提高转基因小鼠研制效率的实验研究

目的建立高效的转基因小鼠制备技术,为开展遗传工程动物模型研究奠定技术基础。方法通过向小鼠受精卵原核中注入不同浓度的DNA分子,筛选最适注射用DNA浓度;将K14/hCTLA4-Ig基因表达载体分子通过显微注射分别导入小鼠受精卵雌、雄原核,并设立单原核注射对照组;利用输卵管腹壶部穿刺移植法将注射后的小鼠受精卵移植于同期发情的受体母鼠;利用PCR对出生的转基因首建小鼠进行筛选。结果最适DNA分子浓度为10ng/μl;在单、双原核注射组胚胎2细胞卵裂率分别为52.3%(132/253)和45.0%(108/240),差异有显著性(P<0.05);注射胚胎移植后体内存活率分别为18.1%(24/132)和16.7%(18/108),差异无显著性;转基因首建小鼠阳性率分别为3/24和5/18,转基因阳性小鼠占总注射胚胎的比例为1.2%(3/253)和2.08%(5/240),差异有极显著性(P<0.01)。结论尽管双原核注射对胚胎的2细胞卵裂率有一定影响,但通过双原核注射可有效提高转基因小鼠的制备效率。     

角质细胞特异性表达Cre重组酶转基因小鼠的建立

构建了含有角质细胞特异性角质素5启动子、Cre重组酶基因和人生长激素基因plyA的转基因载体pK5-Cre-hGH。以显微注射的方法将4．2kb的转基因片段K5-Cre-hGH引入小鼠基因组,共注射720枚受精卵,其中龄5枚移植至29只假孕母鼠的输卵管中发育,获得子代小鼠48只,经基因型鉴定有12只小鼠在其基因组上整合有Cre基因,整合率为25％。将带有cre重组酶基因的小鼠与基因组上携带loxP位点的smad4条件基因打靶小鼠杂交以检测Cre重组酶组织特异性表达情况以及介导重组的功能。结果表明,K5-Cre转基因小鼠只在皮肤组织中表达Cre重组酶并能在体内成功地介导loxP位点的重组。     

Pin1在皮肤组织中的表达以及可诱导转基因小鼠模型的建立

目的观察Pin1在皮肤中的表达情况,构建Pin1在皮肤中可诱导表达的转基因小鼠模型。方法将小鼠Pin1基因克隆到改造过的可与Myc标签蛋白融合的p TRE2载体中,并将线性化的DNA通过显微注射的方式构建TRE-Pin1小鼠。结果成功获得TRE-Pin1转基因首建鼠,该小鼠与上皮特异的K14-rt TA转基因小鼠配繁,获得Pin1在皮肤上皮特异性可诱导表达的双转基因鼠;通过将多西霉素(又名强力霉素,Doxycycline)加入饮水的方式诱导Pin1基因的表达,并通过Western blot,免疫组织化学等方式证明了Pin1蛋白在皮肤上皮中能特异性地过表达。我们还发现内源的Pin1在皮肤中主要表达于上皮细胞。结论成功构建了Pin1在皮肤中可诱导表达的转基因小鼠模型,为后续研究Pin1在皮肤中的功能奠定基础。     

心脏特异性高表达hAPE1基因小鼠的构建与鉴定

本研究拟建立心脏特异性表达hAPE1转基因小鼠,为研究hAPE1基因功能及其突变与心脏发育和心血管疾病的关系提供工具动物。将人APE1(human APE1,hAPE1)基因插入到心脏特异性启动子α-肌球蛋白重链(α-MHC)下游,构建了心肌细胞特异性表达hAPE1的转基因表达载体,显微注射法导入C57BL/6J小鼠受精卵中,经胚胎移植获得转基因首建者小鼠,建立hAPE1转基因小鼠,PCR鉴定转基因小鼠基因型,Western blotting鉴定h APE1蛋白在心脏中的表达并筛选高表达的转基因品系。研究表明,将含有心肌细胞特异性α-MHC启动子和hAPE1基因的转基因载体进行显微注射于小鼠胚胎中,接着将胚胎移植入假孕母鼠的输卵管中发育,建立了心脏组织特异性高表达hAPE1转基因小鼠品系,获得子代小鼠40只。PCR检测发现有15只小鼠在其基因组上整合有hAPE1基因,Western blotting检测hAPE1在这些小鼠心脏中高度特异性表达。本研究成功获得了在小鼠心肌细胞中特异性表达hAPE1的转基因小鼠,为研究基因在心脏发育与相关疾病中的功能提供了有利的工具。     

时空表达可控的转基因动物模型调控体系的研究

目的在血管内皮细胞建立时空表达可控的转基因动物模型调控体系。方法培育两个配套的转基因动物品系,利用组织专一性启动子确保转基因表达的空间专一性,利用四环素诱导系统对转基因表达在时间上实施调控。结果将血管内皮细胞特异性表达的VE cadherin基因启动子与人工融合的转录因子tTA基因连接,建立转基因小鼠品系VE cadherin:tTA;将tetoperon的启动子与myrAkt1连接,建立转基因小鼠品系TET:myrAkt1。两系鼠杂交的子代,筛选的阳性纯合子,能可控性地在血管内皮细胞特异性表达目的基因Akt1PKB。结论利用VE cadherin基因启动子和tet off诱导表达系统,可以达到在时间上和空间上都能人为控制目的基因在血管内皮细胞上特异性表达的目的。     

特异性检测胰腺组织表达Cre重组酶转基因小鼠的方法

利用组织特异性分子标志物启动子调控Cre重组酶,研制了6种在不同组织中特异性表达Cre重组酶的转基因小鼠.这些转基因小鼠的基因型鉴定均使用设计在Cre基因编码区的通用引物.为了特异性检测胰腺组织表达Cre重组酶的转基因小鼠,在大鼠胰岛素RIP启动子上和Cre基因上设计1对引物进行PCR扩增,并通过凝胶电泳进行分析.PCR结果显示,设计在Cre基因上的通用引物可以从6种不同组织特异性Cre重组酶转基因小鼠基因组DNA中扩增获得480 bp产物;利用本研究设计的特异性引物可以从胰腺组织表达Cre重组酶转基因小鼠基因组DNA中扩增200 bp的目的条带.这一结果表明,利用特异性引物进行PCR反应,可有效地将胰腺组织表达Cre重组酶转基因小鼠与其他多种组织的Cm重组酶转基因小鼠鉴别开来.     

组织特异RNAi转基因小鼠模型的构建

RNAi是一种行之有效的基因沉默的新方法,被广泛地应用于基因功能的研究、疾病的治疗以及新型疫苗的研制等领域.本研究通过原核显微注射干扰载体的方法制备转基因小鼠.选用皮肤组织特异表达的人源角蛋白14（K14）基因启动子（2000bp）作为表达载体启动子,成功地驱动融合表达载体EGFP-shRNA进行干扰片段前体的转录,进而生成成熟的干扰片段,靶向小鼠BMP4基因使其发生沉默.所得到的转基因小鼠及其杂交后代经PCR和Southern杂交鉴定,结果表明外源基因准确无误地整合到小鼠基因组.Northern杂交结果证明,小干扰RNA在皮肤组织中有较高水平的表达,在肺和肠组织中有较低水平的表达.研究结果表明,利用PolⅡ型（K14）启动子驱动shRNA融合转录本的表达,在特定组织高表达siRNA,从而达到抑制特定组织目的基因表达的技术路线是可行的.同时为利用K14启动子进行毛囊相关基因干扰研究积累了基础数据,为制备组织特异抑制基因表达的转基因大家畜提供了一个参考方法.     

造血干细胞特异性表达Cre重组酶转基因小鼠的建立

EDAG是在胚胎发育阶段造血干细胞特异性表达的基因.为了在早期造血组织细胞中实现相关基因的条件敲除,构建了含有早期造血组织特异性表达的EDAG启动子和Cre重组酶基因的转基因EDAG-Cre表达载体质粒.通过显微注射的方法将线性化的5.6kb的EDAG-Cre转基因片段导入小鼠受精卵细胞核,获得的新生小鼠经过PCR鉴定,常规方法培育传代.结果发现,共获得了6只阳性转基因首建鼠,其中4只已经建系并稳定传代.RT-PCR分析表明Cre重组酶基因在阳性转基因小鼠的骨髓、脾脏、胸腺、外周血以及胎肝等组织中均有表达,重组酶活性也在脾和骨髓中获得确认.EDAG-Cre重组酶转基因小鼠的建立,为研究早期造血组织以及造血干细胞特异性基因条件敲除小鼠模型的建立奠定了基础.     

胰腺组织表达Cre重组酶转基因小鼠的建立及鉴定

组织特异性表达Cre重组酶的转基因小鼠是进行组织特异性基因剔除研究的重要工具。为了建立胰腺组织特异性Cre转基因小鼠,我们通过PCR克隆了大鼠胰岛素基因启动子,并用它指导Cre基因在胰岛细胞中的特异性表达。在Cre重组酶基因5′端添加了真核核糖体结合序列和核定位序列以使Cre重组酶能穿越核膜在细胞核中发挥功能;同时,在Cre基因3′端添加了含内含子的3′端人生长激素基因。表达载体经显微注射导入小鼠受精卵以建立转基因小鼠。PCR检测显示共获得7只Cre整合阳性的转基因首建者小鼠;RTPCR结果表明其中1只首建者小鼠的子代鼠在胰腺中转录了外源基因,进一步的Southern杂交结果表明,该转基因小鼠能够在胰腺中表达有功能的Cre重组酶。      

Skin-specifically transgenic expression of biologically active human cytoxic T-lymphocyte associated Antigen4-Immunoglobulin (hCTLA4Ig) in mice using lentiviral vector

Xenogeneic skin, especially porcine skin, has already been used to cover large wounds in clinic practice of wound care. Our previous data showed that transgenic expression of human cytoxic T-lymphocyte associated antigen4-immunoglobulin (hCTLA4Ig) in murine skin graft remarkably prolonged its survival in xenogeneic burn wounds without extensive immunosuppression in recipients, suggesting that transgenic hCTLA4Ig expression in skin graft may be an effective and safe method to prolong its survival in xenogeneic wounds for coverage. Lentiviral transgenesis provides an extremely efficient and cost-effective method to produce transgenic animals. However, tissue-targeted transgenic expression of biologically functional protein by lentiviral transgenesis is rarely reported. In this work, a recombinant lentiviral vector (LV), named FKCW in this article, was constructed by inserting a skin-specific hCTLA4Ig expression cassette consisting of keratin 14 (K14) promoter, hCTLA4Ig coding sequence and an intronic fragment. Its efficacy for transgenesis and skin-specific expression of bio-active hCTLA4Ig protein was tested using mice as models. The LV FKCW was readily to be packaged and concentrated to high titres (1.287-6.254 × 10(9) TU/ml) by conventional lentivirus package system. Using eggs collected from only five mated females having been subjected to conventional super-ovulation treatment, 8 hCTLA4Ig transgenic founder mice were generated with the concentrated FKCW vector, and transgenic founder per injected and transferred egg was 6.3%, which was nearly 9-fold higher than that for DNA micro-injection with a similar transgene construct in our previous work. The lentiviral transgenic hCTLA4Ig exhibited strictly skin-specific expression at a level comparable to or even slightly higher than that of transgenic hCTLA4Ig delivered by micro-injection in a similar cassette. Lentiviral transgenic hCTLA4Ig protein remarkably suppressed human lymphocyte proliferation in vitro to a degree comparable to that of commercially purchased purified hCTLA4Ig protein with defined activity at similar concentrations. Besides, lentiviral hCTLA4Ig transgenic mouse skin grafted into rat burn wounds exhibited remarkably extended survival compared to wild-type skin of the same strain (13.8 ± 3.8 vs. 6.8 ± 3.0 days), indicating that lentiviral transgenic hCTLA4Ig did inhibit immune rejection against xenogeneic skin graft in vivo. These results laid down the foundation to further efficiently generate transgenic pigs skin-specifically expressing bio-active hCTLA4Ig by lentiviral transgenesis, and provided a demonstration that transgenic animals with tissue-targeted expression of biologically functional protein can be efficiently produced using LV.     

Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7

The CTLA4 receptor (CD152) on activated T lymphocytes binds B7 molecules (CD80 and CD86) on APC and delivers a signal that inhibits T cell proliferation. Several regions involved in binding to B7 are known, but the relative importance of these is not clear. We have cloned porcine CTLA4 (pCTLA4). Although highly homologous to human CTLA4 (hCTLA4), the predicted protein sequence contains a leucine for methionine substitution at position 97 in the MYPPPY sequence. A fusion protein constructed from the extracellular regions of pCTLA4 and the constant regions of human IgG1 (pCTLA4-Ig) bound porcine CD86 with equivalent affinity to that of hCTLA4-Ig. However, pCTLA4-Ig bound poorly to human CD80 and CD86 expressed on transfectants and EBV-transformed human B cells. In functional assays with MHC class II-expressing porcine endothelial cells and human B cells, pCTLA4-Ig blocked human CD4+ T cell responses to pig but not human cells, whereas control hCTLA4-Ig inhibited responses to both. Comparison between mouse, human, and porcine CTLA4-Ig suggests that the selective binding of pCTLA4-Ig to porcine CD86 molecules is due to the L for M substitution at position 97. Our results indicate that pCTLA4-Ig may be a useful reagent to define the precise nature of the interaction between B7 and CTLA4. By failing to inhibit the delivery of costimulatory signals provided by human B7, it may also prove to be a relatively specific inhibitor of the direct human T cell response to immunogenic pig tissue.     

Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation

The transplantation of fetal porcine neurons is a potential therapeutic strategy for the treatment of human neurodegenerative disorders. A major obstacle to xenotransplantation, however, is the immune-mediated rejection that is resistant to conventional immunosuppression. To determine whether genetically modified donor pig neurons could be used to deliver immunosuppressive proteins locally in the brain, transgenic pigs were developed that express the human T cell inhibitory molecule hCTLA4-Ig under the control of the neuron-specific enolase promoter. Expression was found in various areas of the brain of transgenic pigs, including the mesencephalon, hippocampus and cortex. Neurons from 28-day old embryos secreted hCTLA4-Ig in vitro and this resulted in a 50% reduction of the proliferative response of human T lymphocytes in xenogenic proliferation assays. Transgenic embryonic neurons also secreted hCTLA4-Ig and had developed normally in vivo several weeks after transplantation into the striatum of immunosuppressed rats that were used here to study the engraftment in the absence of immunity. In conclusion, these data show that neurons from our transgenic pigs express hCTLA4-Ig in situ and support the use of this material in future pre-clinical trials in neuron xenotransplantation.Caroline Martin,Martine Plat, Philippe Brachet, Bernard Vanhove - These authors have contributed equally to the development of this work.     

Production and characterization of human CTLA4Ig expressed in transgenic rice cell suspension cultures

Human cytotoxic T-lymphocyte antigen 4-immunoglobulin (hCTLA4I g) fusion protein, a novel immunosuppressive agent, was expressed in transgenic rice cell suspension culture and its characteristics and in vitro activities were investigated. The expression vector pMYN409 was constructed to express hCTLA4I g under the control of rice alpha-amylase 3D (RAmy3D) promoter. Transgenic calli were prepared by particle bombardment mediated transformation and were screened for hCTLA4I g expression using ELISA. Under the induction condition by sugar starvation, suspension-cultured rice cells secreted hCTLA4I g into the media up to 31.4 mg/L in flask culture. The rice-derived hCTLA4Ig (hCTLA4IgP) was purified from the culture media with affinity chromatography using protein A and compared with CHO-derived hCTLA4Ig (hCTLA4IgM). Recombinant hCTLA4IgP has molecular weight of approximately 50 kDa on SDS-PAGE under reducing condition, which is a little different from that of hCTLA4IgM probably due to the difference of carbohydrate chain structures. Purified hCTLA4IgP was biologically active and was confirmed to suppress T-cell proliferation.     

Assessment of Recovery Medium for Production of hCTLA4Ig after Cryopreservation in Transgenic Rice Cells

A reproducible method for cryopreservation of transgenic rice cells (Oryza sativa L. cv. Dongjin) producing recombinant human cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (hCTLA4Ig) has been established. Here, we assessed recovery media and investigated recombinant protein homogeneity after long-term preservation. For recovery of cryopreserved transgenic rice cells, AA medium was suitable in terms of both morphology and production of hCTLA4Ig. There were no differences in cell growth, sugar consumption, and hCTLA4Ig production between non-cryopreserved and cryopreserved cells for up to 1 month. hCTLA4Ig produced from cryopreserved cells was identical that of hCTLA4Ig from non-cryopreserved cells, as determined by analysis of its molecular weight and isoforms. For long-term preservation, cell viability was stably maintained at 61% for 26 months. In conclusion, these results demonstrate the possibility for reproducible cryocell-banking of transgenic rice cells without changes in the characteristics of cells and target proteins.     

Characterization of human cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (hCTLA4Ig) expressed in transgenic rice cell suspension cultures

The avidity for CD80Ig/CD86Ig and the in vitro immunosuppressive effect of recombinant human cytotoxic T lymphocyte-associated antigen 4-immunoglobulin, produced by transgenic rice cell suspension cultures (hCTLA4Ig^P) with CHO-derived recombinant hCTLA4Ig (hCTLA4Ig^M), were measured. Surface plasmon resonance (SPR) was used for kinetic binding analysis: hCTLA4Ig^P and hCTLA4Ig^M had higher avidity for CD80Ig/CD86Ig than for CD28Ig, and the avidity for CD80Ig/CD86Ig was similar. hCTLA4Ig^P and hCTLA4Ig^M had similar in vitro immunosuppressive activity against the expression of T cell-derived cytokines, such as IL-2, IL-4, and IFN-γ, but did not suppress the expression of macrophage-derived cytokines, including TNF-α and IL-1β, as well as NO. Thus the immunosuppressive mechanism of hCTLA4Ig^P is also T cell-specific and it could therefore be used as an immunosuppressive agent with an equivalent potency to that of hCTLA4Ig^M.     

低分子量聚乙亚胺介导的基因转染系统及动物皮肤组织基因转染试验

将带有绿色荧光蛋白(GFP)报告基因的真核表达质粒与阳离子聚合物聚乙亚胺(PEI)结合,用肝癌细胞株CM7221实验,研究其转染效率及可能引起的细胞毒性;进一步用此PEI/DNA复合物转染小鼠皮肤组织,通过报告基因检测,研究转染基因的表达位置及持续表达时间。结果发现,低分子量PEI介导的细胞转染效率最高可达55%,转染效率与PEI结构无关,但是随着分子量的增加,转染活性略有下降。同时,随着分子量的增加,PEI对细胞的毒性也相应的加大;动物皮肤转染实验显示,转染24h后,GFP基因在皮肤组织的毛囊、汗腺、皮脂腺等处高效表达,表达可持续7天。表明低分子量PEI是低毒性、高转染效率的有用非病毒转染载体,能够在动物皮肤组织中进行基因转移,这对皮肤疾病的基因治疗具有潜在的应用价值。     

低分子量聚乙亚胺介导的基因转染系统及动物皮肤组织基因转染试验

将带有绿色荧光蛋白(GFP)报告基因的真核表达质粒与阳离子聚合物聚乙亚胺(PEI)结合,用肝癌细胞株CM7221实验,研究其转染效率及可能引起的细胞毒性;进一步用此PEI／DNA复合物转染小鼠皮肤组织,通过报告基因检测,研究转染基因的表达位置及持续表达时间。结果发现,低分子量PEI介导的细胞转染效率最高可达550%,转染效率与PEI结构无关,但是随着分子量的增加,转染活性略有下降。同时,随着分子量的增加,PEI对细胞的毒性也相应的加大;动物皮肤转染实验显示,转染24h后,GFP基因在皮肤组织的毛囊、汗腺、皮脂腺等处高效表达,表达可持续7天。表明低分子量PEI是低毒性、高转染效率的有用非病毒转染载体,能够在动物皮肤组织中进行基因转移,这对皮肤疾病的基因治疗具有潜在的应用价值。